Business
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide
About this update from Pepgen Inc.
[{"type":"text","content":"BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will be presenting at the 28th Annual Congress of the World Muscle Society, being held October 3-7 in Charleston, South Carolina. Details of the presentations can be found below: 28th Annual Congress of the World Muscle Society, being held October 3-7 in Charleston, South Carolina Title: Phase 1 Study of PGN-EDO51 Demonstrates Tolerability, Delivery, and High Levels of Exon Skipping for Treatment of Duchenne Muscular Dystrophy (DMD)Poster Number: P44Location: Ballroom A-CDate & Time: October 4th at 2:30-3:30pm EDTPresenter: Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development Title: Single – and Repeat – Dose Nonclinical Data for PGN-EDO51 Demonstrate Potential for the Treatment of Duchenne Muscular Dystrophy (DMD) Poster Number: P25Location: Ballroom A-CDate & Time: October 4th at 5:15-6:15pm EDTPresenter: Ashling Holland, Ph.D., Director, Preclinical Development Title: CONNECT-EDO51: Trial Designs to Support the Development of PGN-EDO51 for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Poster Number: P26Location: Ballroom A-CDate & Time: October 4th at 5:15-6:15pm EDTPresenter: Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development Title: Three Novel Enhanced Delivery Oligonucleotide Candidates for Duchenne Muscular Dystrophy Mediate High Levels of Exon 53, 45, and 44 Skipping Poster Number: P27Location: Ballroom A-CDate & Time: October 4th at 5:15-6:15pm EDTPresenter: Ashling Holland, Ph.D., Director, Preclinical Development Title: PGN-EDODM1 Nonclinical Data Demonstrate Mechanistic and Meaningful Activity for Potential Treatment of Myotonic Dystrophy Type 1 (DM1) Poster Number: P390Location: Ballroom A-CDate & Time: October 6th at 2:00-3:00pm EDTPresenter: Ashling Holland, Ph.D., Director, Preclinical Development Title: Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM1 in Adults with Myotonic Dystrophy Type 1 (DM1) Poster Number: P391 Location: Ballroom A-CDate & Time: October 6th at 2:00-3:00pm EDTPresenter: Jennifer Shoskes, Pharm.D., Ass...